The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Combination nivolumab and ipilimumab with and without camu camu in first-line treatment of metastatic renal cell carcinoma (mRCC).
 
Regina Barragan-Carrillo
No Relationships to Disclose
 
Neal Shiv Chawla
No Relationships to Disclose
 
Nicholas Salgia
No Relationships to Disclose
 
Luis A Meza
Honoraria - Ipsen
Travel, Accommodations, Expenses - Ipsen; Ipsen
 
Zeynep Busra Zengin
No Relationships to Disclose
 
Xiaochen Li
No Relationships to Disclose
 
Nazli Dizman
Stock and Other Ownership Interests - Biofarma Ilac (I)
Consulting or Advisory Role - Vivreon Biosciences
 
Hedyeh Ebrahimi
No Relationships to Disclose
 
Joann Hsu
No Relationships to Disclose
 
Daniela V. Castro
No Relationships to Disclose
 
Benjamin D. Mercier
No Relationships to Disclose
 
Tanya B. Dorff
Consulting or Advisory Role - AstraZeneca; Bayer; Exelixis; Janssen Oncology; Sanofi/Aventis
Research Funding - Pfizer (Inst)
 
Abhishek Tripathi
Honoraria - Cardinal Health; Targeted Oncology; Urology times
Consulting or Advisory Role - AADi; Deka Biosciences; EMD Serono; Exelixis; Exelixis; Foundation Medicine; Genzyme; Pfizer; Seagen; Seattle Genetics/Astellas; Seattle Genetics/Astellas
Research Funding - Aravive (Inst); Bayer (Inst); Clovis Oncology (Inst); Corvus Pharmaceuticals (Inst); EMD Serono (Inst); Exact Sciences (Inst); Exelixis (Inst); Pfizer (Inst); WindMIL (Inst)
 
Cristiane Decat Bergerot
No Relationships to Disclose
 
Paulo Gustavo Bergerot
No Relationships to Disclose
 
Alex Chehrazi-Raffle
Honoraria - OncLive/MJH Life Sciences
Consulting or Advisory Role - Tempus
Research Funding - Exelixis
 
Sumanta Kumar Pal
Travel, Accommodations, Expenses - crispr therapeutics; Exelixis; Ipsen